Home / Market News / $RFL
fiscal.ai Corporate Catalyst Impact 85/100 ● positive

Rafael Holdings Subsidiary Submits NDA for Trappsol® Cyclo™

Oct 29, 2026, 1:22 PM UTC · Primary ticker $RFL

Rafael Holdings' subsidiary, Cyclo Therapeutics, submitted a New Drug Application (NDA) to the FDA for remibetadex (Trappsol® Cyclo™) to treat Niemann-Pick Disease Type C. This is a significant positive development for the company, potentially opening a new revenue stream and addressing an unmet medical need for a rare disease.

Rafael Holdings announced that its subsidiary, Cyclo Therapeutics, has submitted a New Drug Application (NDA) to the FDA for remibetadex (Trappsol® Cyclo™) for Niemann-Pick Disease Type C (NPC). This is a critical step towards potential market approval for a drug targeting a rare, progressive genetic disorder with limited treatment options. The submission is supported by Phase 3 trial data, indicating a high likelihood of a thorough review. For Rafael Holdings and Cyclo Therapeutics, this represents a significant long-term opportunity for revenue generation and market penetration in the orphan drug space, while offering hope for NPC patients. Traders should watch for FDA feedback and potential approval timelines, as successful approval would be a major catalyst for RFL and CYTH, though regulatory hurdles remain a short-term risk.

$RFL positive Subsidiary submitted NDA for key drug
$CYTH positive Directly involved in NDA submission
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.